# Anti-PD1-antibody and Pulsed HHI for Advanced BCC

> **NCT04679480** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Reinhard Dummer** · enrollment: 20 (actual)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **DRUG:** Cemiplimab Injection [Libtayo]

## Key facts

- **NCT ID:** NCT04679480
- **Lead sponsor:** Reinhard Dummer
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-02-18
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-07-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679480, "Anti-PD1-antibody and Pulsed HHI for Advanced BCC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04679480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*